The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ∼100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. To overcome this hurdle, scientists from Creative Biolabs have developed single domain antibody technology, which offers blood-brain barrier specific antibodies with implications for the development of biologics-based treatment of brain disorders.
The BBB is a selective interface that restricts movement of molecules between the bloodstream and central nervous system. This barrier imposes a major challenge to the development of therapies for neurological diseases, large molecules in particular, due to the limited ability with which they can penetrate through the BBB. Single domain antibodies are considered as very promising antigen-binding moieties for molecular imaging and therapeutic purposes because of their favorable pharmacological and pharmacokinetic properties. Single domain antibodies have been demonstrated to be able to cross the BBB without treatment, so they can be used as vectors to target drugs or therapeutic peptides into the brain.
Our technology also aims to target endogenous transport systems, including carrier-mediated transporters such as glucose and amino acid carriers, receptor-mediated transcytosis for insulin, transferrin or low-density lipoproteins (LRP1) and the active efflux transporters such as p-glycoprotein.
Creative Biolabs is the recognized leader in single domain antibody production and single domain antibody library fields. We are specialized in generating single domain antibodies against any BBB targets.